Follow The Filings

AZTA Azenta Inc.

Health Care, filed as AZENTA INC (COM), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by AZTA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AZTA insider trades
  • $172K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Ephraim Starr SVP, Gen Counsel & Secretary
    Buy
    $8,096 335 shares at $24.17 +0.5% to stake
    Traded Jul 31 Filed Aug 4
    ↗
  2. William L Cornog Director
    Buy
    $164K 10,000 shares at $16.38 +103% to stake
    Traded May 18 Filed May 19
    ↗
  3. William L Cornog Director
    Buy
    $190K 7,000 shares at $27.13 +37% to stake
    Traded May 16–20 Filed Nov 25, 2025
    ↗
  4. Olga Pirogova SVP and CHRO
    Sale
    $31K 1,085 shares at $28.54 5.6% of stake
    Traded Aug 12, 2025 Filed Nov 14, 2025
    ↗
  5. John Marotta CEO
    Buy
    $26K 1,000 shares at $25.99 +0.9% to stake
    Traded Jun 2, 2025 Filed Nov 14, 2025
    ↗
  6. Alan J Malus Director
    Buy
    $320K 12,000 shares at $26.65 +238% to stake
    Traded May 30, 2025 Filed Nov 14, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 17 stock grants and 8 share withholdings for taxes.

Congress

2 members of Congress traded AZTA in the last three years: 3 buys and 1 sale. 1 member listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 3 filed Apr 7
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Jan 15 filed Feb 13
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Oct 9, 2025 filed Nov 18, 2025
  4. Josh Gottheimer D-NJ-5Joint Sell $1K–$15K Mar 19, 2025 filed Apr 10, 2025

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
8-K 1.01,7.01,8.01 Filing Doc
8-K 2.05,2.06,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.02,7.01 Filing Doc
8-K 5.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 1.01,2.01,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 2.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated about 7 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $665.07M $656.32M $593.82M
Gross profit $263.14M $263.37M $270.28M
Gross margin * 39.6% 40.1% 45.5%
Net income -$14.26M -$164.17M -$55.76M
Net margin * -2.1% -25.0% -9.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.42B $0.833B $0.71B
Total non-current assets * $1.47B $1.27B $1.32B
Total assets $2.89B $2.1B $2.03B
Total current liabilities $210.93M $204.84M $221.05M
Total non-current liabilities * $140.29M $126.24M $117.52M
Total equity $2.53B $1.77B $1.7B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $17.49M $50.29M $72.18M
Cash from investing $431.38M $224.74M -$90.46M
Cash from financing -$844.08M -$659.21M -$9.59M
Net change in cash -$357.25M -$363.06M -$24.3M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.